TriMas Reports First Quarter 2026 Results

Nature’s Sunshine Appoints John Hnanicek as Chief Technology Officer

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

Integer Announces Strategic Review to Maximize Stockholder Value

Diginex Issues Corporate Update Highlighting Strategic AI Transformation, $1.5 Billion Resulticks Acquisition with Strong EBITDA Profile of US$46–50 Million, and Disciplined Funded Growth Strategy

Leidos receives $869 million Army contract to accelerate military decision making

UK Department for Work and Pensions Selects Veritone to Power Workforce Recruitment Strategy

Herbal Dispatch Completes First International Gummy Export, Generates $350,000 in Revenue and Advances Global Edibles Strategy

Taoping Reports Fiscal Year 2025 Results

Restart Life Advances Holy Crap Growth Strategy with New Protein SKU Nearing Commercialization

XCEL BRANDS announces sale of luxury fine jewelry brand Judith Ripka

Kaltura to Announce Financial Results for First Quarter 2026 on Monday, May 11, 2026

New Generation Consumer Group Executes LOI to Acquire Revenue-Generating Operating Business with Approximately $20 Million in Annual Revenue

Kaltura Announces "Connect on the Road 2026 – The Enterprise is Breaking the Fourth Wall" Conference: Join Experts from IBM, AWS, Morgan Stanley, Palo Alto Networks, MetLife, and more in Exploring the End of the Enterprise Monologue

Rezolve Ai Delivers $60 Million Q1 2026 Revenue, Exceeding Full-Year 2025 Revenue in Just 90 Days

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

FIRST BANK APPOINTS ANDY SCOTT AS TRIANGLE REGIONAL EXECUTIVE

Commerce Introduces New Product Innovations Across Storefronts, B2B, Payments and AI-Driven Commerce at Commerce Live 2026

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer